Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2005 May;76(5):656–662. doi: 10.1136/jnnp.2004.042168

The presence of glutamic acid at positions 71 or 74 in pocket 4 of the HLA-DRß1 chain is associated with the clinical course of multiple sclerosis

J Greer 1, M Pender 1
PMCID: PMC1739634  PMID: 15834022

Abstract

Background: Primary progressive multiple sclerosis (PP-MS) differs from relapsing-remitting or secondary progressive MS (RR/SP-MS) in ways suggesting differences in the pathogenic pathways. Susceptibility to both PP-MS and RR/SP-MS is linked to carriage of the HLA molecule DRB1*1501. Several serologically defined HLA-DR groups (DR1, DR4, DR6, and DR9) occur less often in RR/SP-MS than in controls. Some or all of the HLA-DR molecules encoded by alleles in these serologically defined groups have a negatively charged glutamic acid at residue 71 or 74 of the ß1 chain (ß171/ß174). Residues at these positions are important in the formation of pocket 4 in the antigen binding site of the HLA-DR molecule.

Objectives: To investigate whether the presence of alleles encoding HLA-DR molecules containing glutamic acid at ß171/ß174 correlates with the course of MS.

Methods: HLA-DR and HLA-DQ alleles and genotypes were analysed in 121 MS patients (50 with PP-MS) and 109 controls by molecular typing.

Results: Alleles encoding HLA-DR molecules containing a glutamic acid at ß171/ß174 occurred less often in patients with RR/SP-MS than in those with PP-MS or controls. In subjects not carrying the DRB1*1501 allele, a much higher proportion of PP-MS patients carried alleles encoding HLA-DR molecules containing a glutamic acid at ß171/ß174 than did RR/SP-MS patients or controls.

Conclusions: The amino acid residues involved in determining the shape and charge of pocket 4 of the HLA-DR ß1 chain could influence the clinical course of MS by determining protection against RR/SP-MS or susceptibility to the development of PP-MS.

Full Text

The Full Text of this article is available as a PDF (217.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alvarado-de la Barrera C., Zúiga-Ramos J., Ruíz-Morales J. A., Estañol B., Granados J., Llorente L. HLA class II genotypes in Mexican Mestizos with familial and nonfamilial multiple sclerosis. Neurology. 2000 Dec 26;55(12):1897–1900. doi: 10.1212/wnl.55.12.1897. [DOI] [PubMed] [Google Scholar]
  2. Bashir K., Whitaker J. N. Clinical and laboratory features of primary progressive and secondary progressive MS. Neurology. 1999 Sep 11;53(4):765–771. doi: 10.1212/wnl.53.4.765. [DOI] [PubMed] [Google Scholar]
  3. Bielekova B., Goodwin B., Richert N., Cortese I., Kondo T., Afshar G., Gran B., Eaton J., Antel J., Frank J. A. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med. 2000 Oct;6(10):1167–1175. doi: 10.1038/80516. [DOI] [PubMed] [Google Scholar]
  4. Caballero A., Alvés-León S., Papais-Alvarenga R., Fernández O., Navarro G., Alonso A. DQB1*0602 confers genetic susceptibility to multiple sclerosis in Afro-Brazilians. Tissue Antigens. 1999 Nov;54(5):524–526. doi: 10.1034/j.1399-0039.1999.540511.x. [DOI] [PubMed] [Google Scholar]
  5. Celius E. G., Harbo H. F., Egeland T., Vartdal F., Vandvik B., Spurkiand A. Sex and age at diagnosis are correlated with the HLA-DR2, DQ6 haplotype in multiple sclerosis. J Neurol Sci. 2000 Sep 15;178(2):132–135. doi: 10.1016/s0022-510x(00)00389-0. [DOI] [PubMed] [Google Scholar]
  6. Cottrell D. A., Kremenchutzky M., Rice G. P., Koopman W. J., Hader W., Baskerville J., Ebers G. C. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain. 1999 Apr;122(Pt 4):625–639. doi: 10.1093/brain/122.4.625. [DOI] [PubMed] [Google Scholar]
  7. Djoulah S., Busson M., Sasazuki T., Maillere B., Yasunaga S., Kimura A., Charron D., Hors J. A new predictive model for insulin-dependent diabetes mellitus susceptibility based on combinations of molecular HLA-DRB1 and HLA-DQB1 pockets. Tissue Antigens. 1999 Oct;54(4):341–348. doi: 10.1034/j.1399-0039.1999.540403.x. [DOI] [PubMed] [Google Scholar]
  8. Ebers George C. Natural history of primary progressive multiple sclerosis. Mult Scler. 2004 Jun;10 (Suppl 1):S8–S15. doi: 10.1191/1352458504ms1025oa. [DOI] [PubMed] [Google Scholar]
  9. Greer J. M., Csurhes P. A., Cameron K. D., McCombe P. A., Good M. F., Pender M. P. Increased immunoreactivity to two overlapping peptides of myelin proteolipid protein in multiple sclerosis. Brain. 1997 Aug;120(Pt 8):1447–1460. doi: 10.1093/brain/120.8.1447. [DOI] [PubMed] [Google Scholar]
  10. Guex N., Peitsch M. C. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis. 1997 Dec;18(15):2714–2723. doi: 10.1002/elps.1150181505. [DOI] [PubMed] [Google Scholar]
  11. Haas J. P., Nevinny-Stickel C., Schoenwald U., Truckenbrodt H., Suschke J., Albert E. D. Susceptible and protective major histocompatibility complex class II alleles in early-onset pauciarticular juvenile chronic arthritis. Hum Immunol. 1994 Nov;41(3):225–233. doi: 10.1016/0198-8859(94)90040-x. [DOI] [PubMed] [Google Scholar]
  12. Hammer J., Gallazzi F., Bono E., Karr R. W., Guenot J., Valsasnini P., Nagy Z. A., Sinigaglia F. Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association. J Exp Med. 1995 May 1;181(5):1847–1855. doi: 10.1084/jem.181.5.1847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hauser S. L., Fleischnick E., Weiner H. L., Marcus D., Awdeh Z., Yunis E. J., Alper C. A. Extended major histocompatibility complex haplotypes in patients with multiple sclerosis. Neurology. 1989 Feb;39(2 Pt 1):275–277. doi: 10.1212/wnl.39.2.275. [DOI] [PubMed] [Google Scholar]
  14. Hellings Niels, Raus Jef, Stinissen Piet. Insights into the immunopathogenesis of multiple sclerosis. Immunol Res. 2002;25(1):27–51. doi: 10.1385/IR:25:1:27. [DOI] [PubMed] [Google Scholar]
  15. Henderson R. D., Bain C. J., Pender M. P. The occurrence of autoimmune diseases in patients with multiple sclerosis and their families. J Clin Neurosci. 2000 Sep;7(5):434–437. doi: 10.1054/jocn.2000.0693. [DOI] [PubMed] [Google Scholar]
  16. Hennecke Jens, Wiley Don C. Structure of a complex of the human alpha/beta T cell receptor (TCR) HA1.7, influenza hemagglutinin peptide, and major histocompatibility complex class II molecule, HLA-DR4 (DRA*0101 and DRB1*0401): insight into TCR cross-restriction and alloreactivity. J Exp Med. 2002 Mar 4;195(5):571–581. doi: 10.1084/jem.20011194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Hillert J., Grönning M., Nyland H., Link H., Olerup O. An immunogenetic heterogeneity in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1992 Oct;55(10):887–890. doi: 10.1136/jnnp.55.10.887. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hillert J., Olerup O. Multiple sclerosis is associated with genes within or close to the HLA-DR-DQ subregion on a normal DR15,DQ6,Dw2 haplotype. Neurology. 1993 Jan;43(1):163–168. doi: 10.1212/wnl.43.1_part_1.163. [DOI] [PubMed] [Google Scholar]
  19. Karni A., Kohn Y., Safirman C., Abramsky O., Barcellos L., Oksenberg J. R., Kahana E., Karussis D., Chapman J., Brautbar C. Evidence for the genetic role of human leukocyte antigens in low frequency DRB1*1501 multiple sclerosis patients in Israel. Mult Scler. 1999 Dec;5(6):410–415. doi: 10.1177/135245859900500i607. [DOI] [PubMed] [Google Scholar]
  20. Knip Mikael, Kukko Marika, Kulmala Petri, Veijola Riitta, Simell Olli, Akerblom Hans K., Ilonen Jorma. Humoral beta-cell autoimmunity in relation to HLA-defined disease susceptibility in preclinical and clinical type 1 diabetes. Am J Med Genet. 2002 May 30;115(1):48–54. doi: 10.1002/ajmg.10343. [DOI] [PubMed] [Google Scholar]
  21. Kwon O. J., Karni A., Israel S., Brautbar C., Amar A., Meiner Z., Abramsky O., Karussis D. HLA class II susceptibility to multiple sclerosis among Ashkenazi and non-Ashkenazi Jews. Arch Neurol. 1999 May;56(5):555–560. doi: 10.1001/archneur.56.5.555. [DOI] [PubMed] [Google Scholar]
  22. Lefranc Didier, Almeras Lionel, Dubucquoi Sylvain, de Seze Jérôme, Vermersch Patrick, Prin Lionel. Distortion of the self-reactive IgG antibody repertoire in multiple sclerosis as a new diagnostic tool. J Immunol. 2004 Jan 1;172(1):669–678. doi: 10.4049/jimmunol.172.1.669. [DOI] [PubMed] [Google Scholar]
  23. Marrosu M. G., Murru M. R., Costa G., Murru R., Muntoni F., Cucca F. DRB1-DQA1-DQB1 loci and multiple sclerosis predisposition in the Sardinian population. Hum Mol Genet. 1998 Aug;7(8):1235–1237. doi: 10.1093/hmg/7.8.1235. [DOI] [PubMed] [Google Scholar]
  24. Martin R., McFarland H. F., McFarlin D. E. Immunological aspects of demyelinating diseases. Annu Rev Immunol. 1992;10:153–187. doi: 10.1146/annurev.iy.10.040192.001101. [DOI] [PubMed] [Google Scholar]
  25. Masterman T., Ligers A., Olsson T., Andersson M., Olerup O., Hillert J. HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann Neurol. 2000 Aug;48(2):211–219. [PubMed] [Google Scholar]
  26. McDonald W. I., Compston A., Edan G., Goodkin D., Hartung H. P., Lublin F. D., McFarland H. F., Paty D. W., Polman C. H., Reingold S. C. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001 Jul;50(1):121–127. doi: 10.1002/ana.1032. [DOI] [PubMed] [Google Scholar]
  27. McDonnell G. V., Cabrera-Gomez J., Calne D. B., Li D. K. B., Oger J. Clinical presentation of primary progressive multiple sclerosis 10 years after the incidental finding of typical magnetic resonance imaging brain lesions: the subclinical stage of primary progressive multiple sclerosis may last 10 years. Mult Scler. 2003 Mar;9(2):204–209. doi: 10.1191/1352458503ms890cr. [DOI] [PubMed] [Google Scholar]
  28. McDonnell G. V., Hawkins S. A. Primary progressive multiple sclerosis: increasing clarity but many unanswered questions. J Neurol Sci. 2002 Jul 15;199(1-2):1–15. doi: 10.1016/s0022-510x(02)00053-9. [DOI] [PubMed] [Google Scholar]
  29. McDonnell G. V., Mawhinney H., Graham C. A., Hawkins S. A., Middleton D. A study of the HLA-DR region in clinical subgroups of multiple sclerosis and its influence on prognosis. J Neurol Sci. 1999 May 1;165(1):77–83. doi: 10.1016/s0022-510x(99)00084-2. [DOI] [PubMed] [Google Scholar]
  30. Miller S. A., Dykes D. D., Polesky H. F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988 Feb 11;16(3):1215–1215. doi: 10.1093/nar/16.3.1215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Myhre Anne Grethe, Undlien Dag E., Løvås Kristian, Uhlving Sverre, Nedrebø Bjørn G., Fougner Kristian J., Trovik Thor, Sørheim Jan I., Husebye Eystein S. Autoimmune adrenocortical failure in Norway autoantibodies and human leukocyte antigen class II associations related to clinical features. J Clin Endocrinol Metab. 2002 Feb;87(2):618–623. doi: 10.1210/jcem.87.2.8192. [DOI] [PubMed] [Google Scholar]
  32. Olerup O., Hillert J., Fredrikson S., Olsson T., Kam-Hansen S., Möller E., Carlsson B., Wallin J. Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities. Proc Natl Acad Sci U S A. 1989 Sep;86(18):7113–7117. doi: 10.1073/pnas.86.18.7113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Olerup O., Hillert J. HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation. Tissue Antigens. 1991 Jul;38(1):1–15. doi: 10.1111/j.1399-0039.1991.tb02029.x. [DOI] [PubMed] [Google Scholar]
  34. Pender Michael P., Csurhes Peter A., Wolfe Nigel P., Hooper Kaye D., Good Michael F., McCombe Pamela A., Greer Judith M. Increased circulating T cell reactivity to GM3 and GQ1b gangliosides in primary progressive multiple sclerosis. J Clin Neurosci. 2003 Jan;10(1):63–66. doi: 10.1016/s0967-5868(02)00270-9. [DOI] [PubMed] [Google Scholar]
  35. Poser C. M., Paty D. W., Scheinberg L., McDonald W. I., Davis F. A., Ebers G. C., Johnson K. P., Sibley W. A., Silberberg D. H., Tourtellotte W. W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983 Mar;13(3):227–231. doi: 10.1002/ana.410130302. [DOI] [PubMed] [Google Scholar]
  36. Price P., Witt C., Allcock R., Sayer D., Garlepp M., Kok C. C., French M., Mallal S., Christiansen F. The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunol Rev. 1999 Feb;167:257–274. doi: 10.1111/j.1600-065x.1999.tb01398.x. [DOI] [PubMed] [Google Scholar]
  37. Richeldi L., Sorrentino R., Saltini C. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. Science. 1993 Oct 8;262(5131):242–244. doi: 10.1126/science.8105536. [DOI] [PubMed] [Google Scholar]
  38. Sadatipour B. T., Greer J. M., Pender M. P. Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. Ann Neurol. 1998 Dec;44(6):980–983. doi: 10.1002/ana.410440621. [DOI] [PubMed] [Google Scholar]
  39. Saruhan-Direskeneli G., Esin S., Baykan-Kurt B., Ornek I., Vaughan R., Eraksoy M. HLA-DR and -DQ associations with multiple sclerosis in Turkey. Hum Immunol. 1997 Jun;55(1):59–65. doi: 10.1016/s0198-8859(97)00086-4. [DOI] [PubMed] [Google Scholar]
  40. Schreuder G. M., Hurley C. K., Marsh S. G., Lau M., Maiers M., Kollman C., Noreen H. J. The HLA Dictionary 2001: a summary of HLA-A, -B, -C, -DRB1/3/4/5, -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR and -DQ antigens. Tissue Antigens. 2001 Aug;58(2):109–140. doi: 10.1034/j.1399-0039.2001.580210.x. [DOI] [PubMed] [Google Scholar]
  41. Smith K. J., Pyrdol J., Gauthier L., Wiley D. C., Wucherpfennig K. W. Crystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic protein. J Exp Med. 1998 Oct 19;188(8):1511–1520. doi: 10.1084/jem.188.8.1511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Stenström Gunnar, Berger Bo, Borg Henrik, Fernlund Per, Dorman Janice S., Sundkvist Göran. HLA-DQ genotypes in classic type 1 diabetes and in latent autoimmune diabetes of the adult. Am J Epidemiol. 2002 Nov 1;156(9):787–796. doi: 10.1093/aje/kwf115. [DOI] [PubMed] [Google Scholar]
  43. Stern L. J., Brown J. H., Jardetzky T. S., Gorga J. C., Urban R. G., Strominger J. L., Wiley D. C. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature. 1994 Mar 17;368(6468):215–221. doi: 10.1038/368215a0. [DOI] [PubMed] [Google Scholar]
  44. Stewart G. J., Basten A., Guinan J., Bashir H. V., Cameron J., McLeod J. G. HLA-DW2, viral immunity and family studies in multiple sclerosis. J Neurol Sci. 1977 Jun;32(2):153–167. doi: 10.1016/0022-510x(77)90231-3. [DOI] [PubMed] [Google Scholar]
  45. Thompson A. J., Kermode A. G., MacManus D. G., Kendall B. E., Kingsley D. P., Moseley I. F., McDonald W. I. Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. BMJ. 1990 Mar 10;300(6725):631–634. doi: 10.1136/bmj.300.6725.631. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Wang F. W., Yu Z. Q., Xy J. J., Wang X. L., Zhang D. Q., Chen J. L. HLA and hypertrophic Hashimoto's thyroiditis in Shanghai Chinese. Tissue Antigens. 1988 Oct;32(4):235–236. doi: 10.1111/j.1399-0039.1988.tb01661.x. [DOI] [PubMed] [Google Scholar]
  47. Wassmuth Ralf, Wagner Ulf. Prognostic use of human leukocyte antigen genotyping for rheumatoid arthritis susceptibility, disease course, and clinical stratification. Rheum Dis Clin North Am. 2002 Feb;28(1):17–37. doi: 10.1016/s0889-857x(03)00067-x. [DOI] [PubMed] [Google Scholar]
  48. Weinshenker B. G., Santrach P., Bissonet A. S., McDonnell S. K., Schaid D., Moore S. B., Rodriguez M. Major histocompatibility complex class II alleles and the course and outcome of MS: a population-based study. Neurology. 1998 Sep;51(3):742–747. doi: 10.1212/wnl.51.3.742. [DOI] [PubMed] [Google Scholar]
  49. Wucherpfennig K. W., Yu B., Bhol K., Monos D. S., Argyris E., Karr R. W., Ahmed A. R., Strominger J. L. Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris. Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11935–11939. doi: 10.1073/pnas.92.25.11935. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Zerva L., Cizman B., Mehra N. K., Alahari S. K., Murali R., Zmijewski C. M., Kamoun M., Monos D. S. Arginine at positions 13 or 70-71 in pocket 4 of HLA-DRB1 alleles is associated with susceptibility to tuberculoid leprosy. J Exp Med. 1996 Mar 1;183(3):829–836. doi: 10.1084/jem.183.3.829. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Zipp F., Windemuth C., Pankow H., Dichgans J., Wienker T., Martin R., Müller C. Multiple sclerosis associated amino acids of polymorphic regions relevant for the HLA antigen binding are confined to HLA-DR2. Hum Immunol. 2000 Oct;61(10):1021–1030. doi: 10.1016/s0198-8859(00)00173-7. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES